Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Israa Al-Shakarchi"'
Publikováno v:
Rheumatology. 62
Background/Aims Baricitinib is the most common Janus Kinase inhibitor (JAKi) used in the treatment of rheumatological conditions. Whilst randomised controlled trials have demonstrated the efficacy and safety profile of baricitinib, real-world data on
Autor:
Helena Robinson, Resmy Suresh, Sumeet Chander, Nidhi Sofat, Arvind Kaul, Amara Ezeonyeji, Pratyasha Saha, Virinderjit Sandhu, Israa Al-Shakarchi
Publikováno v:
Rheumatology. 59
Background Tocilizumab is now approved by the National Institute of Health and Care Excellence (NICE) for up to a year in relapsing or refractory giant cell arteritis (GCA). The practicalities of developing a pathway for referral using a hub and spok
Autor:
Israa Al-Shakarchi, Gerald Coakley
Publikováno v:
Medicine. 46:166-169
Infection, crystal arthropathies, osteoarthritis, trauma and a variety of systemic diseases can all lead to a painful, swollen peripheral joint of which septic arthritis is the most serious cause. Synovial fluid (SF) analysis is widely used to aid th
Publikováno v:
Rheumatology Advances in Practice
Introduction Giant cell arteritis (GCA) represents a common cause of uncertainty for physicians. GCA can present as an indolent or aggressive process with a wide spectrum of symptoms and signs. The key to diagnosis is good clinical acumen and awarene
Autor:
Samir Patel, Israa Al-Shakarchi
Publikováno v:
Rheumatology Advances in Practice
Introduction Despite being the most common form of primary systemic vasculitis in adults, giant cell arteritis (GCA) remains a difficult diagnosis to make due to the breadth and versatility of presenting symptoms and signs. Many patients present with
Publikováno v:
Patient preference and adherence
Rheumatoid arthritis (RA) remains a major clinical problem with many patients having continuing systemic inflammatory disease resulting in progressive erosive damage and high levels of disability. A range of pro-inflammatory cytokines including tumor